Columbia Engineering Develops Injectable RNA Therapy That Turns Skeletal Muscle into a Heart-Repairing Drug Factory

New RNA-based injection from Columbia University turns muscle into a drug factory to repair heart damage, offering a non-invasive alternative to surgery.

By: AXL Media

Published: Mar 14, 2026, 11:34 AM EDT

Source: Information for this report was sourced from Columbia University School of Engineering and Applied Science

Overcoming the Regenerative Limits of the Adult Heart

The human heart is notorious for its inability to replace muscle cells lost during a traumatic event such as a heart attack. According to Ke Cheng, a professor of biomedical engineering at Columbia University, the organ's natural power to regenerate is extremely limited, leaving many survivors with permanent damage that eventually leads to heart failure. In a study published in Science, researchers describe a novel therapy designed to bypass these biological constraints by harnessing RNA technology to stimulate the heart’s internal protection and repair mechanisms without the need for invasive surgery.

Harnessing the Genetic Secrets of Neonatal Healing

The inspiration for this breakthrough came from the observation that newborn mammals possess a fleeting ability to regenerate heart tissue during the first days of life. According to the research team, this capacity is driven by a hormone called atrial natriuretic peptide, or ANP, which reduces inflammation and promotes the growth of new blood vessels. While the gene responsible for this hormone—Nppa—is highly active in infants, its output drops significantly in adults. By supplementing this natural molecule through RNA delivery, the team successfully restored neonatal-like healing properties to adult animal models.

Turning Skeletal Muscle into a Bio-Production Hub

Delivering medication directly to the heart has historically been a major bottleneck in cardiology, often requiring direct injections into the heart muscle or arterial stents. According to the study, Columbia engineers solved this by developing a two-phase approach that utilizes the patient's thigh or arm muscle. By injecting self-amplifying RNA-lipid nanoparticles into the skeletal muscle, the body begins producing a "prodrug" called pro-ANP. This inactive molecule circulates safely through the bloodstream until it encounters a specific enzyme called Corin.